Clinical trial
A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
NCT06848699
Study timeline
Study start (actual)2025-02-25Date precision: day
Registry last updated2025-11-17
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Solid Tumor Cancerunresolved
Non Small Cell Lung Cancerunresolved
Interventions
Sponsors & collaborators
Shanghai Henlius Biotechlead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT06848699 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.